Price to Sales (P/S)
since 2005
Calculation
Gilead Sciences Inc., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Product sales1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | 6.34 | = | 147.64 | ÷ | 23.29 | 23.29 | = | 28,915 | ÷ | 1,241,420,528 | |
| Feb 28, 2025 | 4.98 | = | 114.31 | ÷ | 22.97 | 22.97 | = | 28,610 | ÷ | 1,245,346,062 | |
| Feb 23, 2024 | 3.40 | = | 73.55 | ÷ | 21.62 | 21.62 | = | 26,934 | ÷ | 1,245,774,616 | |
| Feb 22, 2023 | 3.86 | = | 83.50 | ÷ | 21.64 | 21.64 | = | 26,982 | ÷ | 1,247,105,154 | |
| Feb 23, 2022 | 2.85 | = | 61.35 | ÷ | 21.54 | 21.54 | = | 27,008 | ÷ | 1,253,886,724 | |
| Feb 25, 2021 | 3.24 | = | 62.79 | ÷ | 19.38 | 19.38 | = | 24,355 | ÷ | 1,256,593,156 | |
| Feb 25, 2020 | 4.00 | = | 70.10 | ÷ | 17.50 | 17.50 | = | 22,119 | ÷ | 1,263,636,656 | |
| Feb 26, 2019 | 3.84 | = | 65.28 | ÷ | 16.99 | 16.99 | = | 21,677 | ÷ | 1,275,510,558 | |
| Feb 27, 2018 | 4.10 | = | 80.36 | ÷ | 19.59 | 19.59 | = | 25,662 | ÷ | 1,309,967,781 | |
| Feb 27, 2017 | 3.08 | = | 70.50 | ÷ | 22.92 | 22.92 | = | 29,953 | ÷ | 1,307,066,900 | |
| Feb 24, 2016 | 3.80 | = | 89.36 | ÷ | 23.52 | 23.52 | = | 32,151 | ÷ | 1,366,845,691 | |
| Feb 25, 2015 | 6.36 | = | 104.43 | ÷ | 16.43 | 16.43 | = | 24,474 | ÷ | 1,489,401,683 | |
| Feb 25, 2014 | 11.95 | = | 83.95 | ÷ | 7.02 | 7.02 | = | 10,804 | ÷ | 1,538,252,914 | |
| Feb 27, 2013 | 6.95 | = | 42.89 | ÷ | 6.17 | 6.17 | = | 9,398 | ÷ | 1,522,392,518 | |
| Feb 23, 2012 | 4.22 | = | 22.58 | ÷ | 5.35 | 5.35 | = | 8,102 | ÷ | 1,514,630,722 | |
| Feb 28, 2011 | 4.19 | = | 19.49 | ÷ | 4.65 | 4.65 | = | 7,390 | ÷ | 1,590,529,288 | |
| Mar 1, 2010 | 6.64 | = | 23.76 | ÷ | 3.58 | 3.58 | = | 6,469 | ÷ | 1,806,757,972 | |
| Feb 27, 2009 | 8.03 | = | 22.40 | ÷ | 2.79 | 2.79 | = | 5,085 | ÷ | 1,821,909,204 | |
| Feb 27, 2008 | 10.90 | = | 21.90 | ÷ | 2.01 | 2.01 | = | 3,733 | ÷ | 1,857,740,064 | |
| Feb 27, 2007 | 12.67 | = | 17.65 | ÷ | 1.39 | 1.39 | = | 2,588 | ÷ | 1,858,655,664 | |
| Mar 3, 2006 | 15.36 | = | 15.03 | ÷ | 0.98 | 0.98 | = | 1,809 | ÷ | 1,849,138,544 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Gilead Sciences Inc. Annual Report.
The price-to-sales (P/S) ratio, calculated from the provided share price and sales per share figures, exhibits considerable fluctuation over the observed period. Initially, a decreasing trend is apparent, followed by periods of relative stability and subsequent increases. A detailed examination reveals distinct phases in the ratio’s behavior.
- Initial Decline (2006-2009)
- From 2006 to 2009, the P/S ratio demonstrates a consistent decline, moving from 15.36 to 8.03. This suggests that the market valuation of the company’s sales decreased during this timeframe, potentially reflecting changing investor sentiment or expectations regarding future growth.
- Period of Low Ratios (2010-2011)
- The years 2010 and 2011 show the lowest P/S ratios in the series, reaching 6.64 and 4.19 respectively. This indicates a particularly low valuation relative to sales during these years. The substantial increase in sales per share during this period did not translate into a corresponding increase in share price, resulting in the lower ratio.
- Volatility and Peak (2012-2015)
- Following 2011, the P/S ratio experiences increased volatility. It rises to 6.95 in 2013, peaks at 11.95 in 2014, and then declines sharply to 6.36 in 2015. This period likely reflects significant events or changes within the company that impacted investor perception. The large increase in sales per share in 2015 contributed to the initial decline in the P/S ratio despite a rising share price.
- Stabilization and Recent Trends (2016-2026)
- From 2016 onwards, the P/S ratio generally stabilizes, fluctuating between approximately 3.08 and 6.34. A slight upward trend is observed in the most recent years, with the ratio increasing from 3.86 in 2019 to 6.34 in 2026. This suggests a renewed investor confidence or a shift in market expectations regarding the company’s future performance. The ratio nearly doubled from 2023 to 2026, indicating a significant increase in valuation relative to sales.
Overall, the P/S ratio demonstrates a complex pattern over the period examined. While an initial decline and subsequent low ratios were observed, more recent years show a trend towards stabilization and a moderate increase, suggesting evolving market dynamics and company performance.
AI Ask an analyst for more
Comparison to Competitors
Gilead Sciences Inc., P/S, long-term trends, comparison to competitors
| Gilead Sciences Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | 6.34 | 6.50 | 5.66 | 2.53 | 6.02 | 15.03 | 6.16 | 4.71 | 2.46 | 5.71 | 4.34 | 10.40 |
| Feb 28, 2025 | 4.98 | 6.04 | 4.88 | 2.36 | 6.23 | 18.25 | 4.26 | 3.60 | 2.32 | 5.52 | 4.73 | 10.78 |
| Feb 23, 2024 | 3.40 | 5.72 | 5.78 | 2.19 | 7.76 | 20.77 | 4.43 | 5.43 | 2.61 | 7.84 | 4.99 | 11.16 |
| Feb 22, 2023 | 3.86 | 4.61 | 5.17 | 3.29 | 5.79 | 10.96 | 4.34 | 4.71 | 2.35 | 7.01 | 4.73 | 8.56 |
| Feb 23, 2022 | 2.85 | 4.53 | 5.10 | 3.16 | 6.37 | 8.01 | 4.66 | 3.96 | 3.15 | 4.20 | 5.39 | 8.21 |
| Feb 25, 2021 | 3.24 | 4.05 | 5.64 | 3.16 | 7.01 | 8.06 | 5.15 | 3.93 | 4.42 | 6.24 | 5.52 | 8.82 |
| Feb 25, 2020 | 4.00 | 4.22 | 6.03 | 5.52 | 6.29 | 6.03 | 4.79 | 4.33 | 3.66 | 5.34 | 4.83 | 14.95 |
| Feb 26, 2019 | 3.84 | 3.58 | 5.22 | 3.67 | 3.97 | 5.15 | 4.45 | 4.92 | 4.49 | 6.62 | 4.24 | 15.54 |
| Feb 27, 2018 | 4.10 | 6.67 | 5.82 | 5.02 | 3.70 | 3.71 | 4.56 | 3.68 | 4.05 | 5.92 | 4.01 | 16.42 |
| Feb 27, 2017 | 3.08 | 3.84 | 5.65 | 4.72 | 3.48 | 4.18 | 4.62 | 4.54 | 3.84 | 7.86 | 3.37 | 12.51 |
| Feb 24, 2016 | 3.80 | 3.83 | 5.28 | 6.07 | 2.91 | 4.02 | 4.13 | 3.56 | 3.76 | 9.38 | 3.05 | 20.38 |
| Feb 25, 2015 | 6.36 | 4.90 | 6.13 | 6.28 | 3.09 | 4.03 | 3.77 | 3.93 | 4.24 | 14.62 | 3.06 | 47.41 |
| Feb 25, 2014 | 11.95 | 4.31 | 5.22 | 5.48 | 2.78 | 2.81 | 3.63 | 3.78 | 3.97 | 15.52 | 3.74 | 16.53 |
| Feb 27, 2013 | 6.95 | 3.30 | 4.09 | 3.40 | 2.32 | 2.71 | 3.17 | 2.73 | 3.34 | 11.66 | 2.12 | 6.60 |
| Feb 23, 2012 | 4.22 | — | 3.52 | 2.63 | 2.28 | 1.87 | 2.75 | 2.43 | 2.37 | 20.90 | 1.77 | 5.61 |
| Feb 28, 2011 | 4.19 | — | 3.32 | 2.23 | 2.48 | 1.73 | 2.65 | 2.18 | 2.27 | 7.38 | 2.00 | 56.82 |
| Mar 1, 2010 | 6.64 | — | 3.88 | 2.27 | 2.16 | 1.82 | 2.82 | 4.23 | 2.83 | 5.74 | 1.98 | 80.12 |
| Feb 27, 2009 | 8.03 | — | 3.44 | 1.96 | 1.30 | 1.66 | 2.37 | 2.14 | 1.72 | 5.17 | 1.44 | 28.70 |
| Feb 27, 2008 | 10.90 | — | 3.46 | 2.30 | 2.16 | 3.05 | 2.95 | 4.04 | 3.11 | 11.94 | 2.40 | 12.17 |
| Feb 27, 2007 | 12.67 | — | 5.41 | 3.07 | 2.30 | 3.80 | 3.53 | 4.23 | 3.67 | 19.70 | 5.05 | 17.58 |
| Mar 3, 2006 | 15.36 | — | 7.24 | 2.34 | 2.40 | 4.31 | 3.49 | 3.50 | 3.77 | 14.06 | 2.15 | 26.93 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Gilead Sciences Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Gilead Sciences Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 24, 2026 | 6.34 | 6.24 |
| Feb 28, 2025 | 4.98 | 5.55 |
| Feb 23, 2024 | 3.40 | 5.89 |
| Feb 22, 2023 | 3.86 | 4.56 |
| Feb 23, 2022 | 2.85 | 4.50 |
| Feb 25, 2021 | 3.24 | 4.90 |
| Feb 25, 2020 | 4.00 | 4.88 |
| Feb 26, 2019 | 3.84 | 4.54 |
| Feb 27, 2018 | 4.10 | 4.60 |
| Feb 27, 2017 | 3.08 | 4.29 |
| Feb 24, 2016 | 3.80 | 4.10 |
| Feb 25, 2015 | 6.36 | 4.54 |
| Feb 25, 2014 | 11.95 | 4.30 |
| Feb 27, 2013 | 6.95 | 3.25 |
| Feb 23, 2012 | 4.22 | 2.58 |
| Feb 28, 2011 | 4.19 | 2.44 |
| Mar 1, 2010 | 6.64 | 3.00 |
| Feb 27, 2009 | 8.03 | 2.22 |
| Feb 27, 2008 | 10.90 | 3.19 |
| Feb 27, 2007 | 12.67 | 3.88 |
| Mar 3, 2006 | 15.36 | 3.84 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Gilead Sciences Inc., P/S, long-term trends, comparison to industry (health care)
| Gilead Sciences Inc. | Health Care | |
|---|---|---|
| Feb 24, 2026 | 6.34 | 3.34 |
| Feb 28, 2025 | 4.98 | 3.36 |
| Feb 23, 2024 | 3.40 | 3.52 |
| Feb 22, 2023 | 3.86 | 51,413.66 |
| Feb 23, 2022 | 2.85 | 3.28 |
| Feb 25, 2021 | 3.24 | 3.31 |
| Feb 25, 2020 | 4.00 | 3.21 |
| Feb 26, 2019 | 3.84 | 3.07 |
| Feb 27, 2018 | 4.10 | 3.06 |
| Feb 27, 2017 | 3.08 | 2.80 |
| Feb 24, 2016 | 3.80 | 2.72 |
| Feb 25, 2015 | 6.36 | 3.08 |
| Feb 25, 2014 | 11.95 | 2.81 |
| Feb 27, 2013 | 6.95 | 2.20 |
| Feb 23, 2012 | 4.22 | 1.90 |
| Feb 28, 2011 | 4.19 | 1.80 |
| Mar 1, 2010 | 6.64 | 2.08 |
| Feb 27, 2009 | 8.03 | 1.70 |
| Feb 27, 2008 | 10.90 | 2.42 |
| Feb 27, 2007 | 12.67 | 2.85 |
| Mar 3, 2006 | 15.36 | 3.17 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).